 |
Cougar Biotechnology, Inc. is a Los Angeles-based publicly traded biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, which is currently in a Phase I/II trial in multiple myeloma; and CB1089, which has been clinically tested in a number of solid tumor types.
On February 8, 2007, Cougar began trading on the OTC Bulletin Board® under the symbol "CGRB.OB." Cougar's common stock was approved for listing on The NASDAQ Global Market and began trading on NASDAQ under the symbol "CGRB" on December 7, 2007.
|
Cougar Biotechnology (NASDAQ: CGRB) .
|
|
()
|
|
|
|
|
|
| | |
Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax |
